<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>P2Y1, P2X1, and P2T receptors mediate <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation </plain></SENT>
<SENT sid="1" pm="."><plain>The antithrombotic effects of AR-C69931MX (N6-[2-<z:chebi fb="0" ids="48563">methylthio</z:chebi>)ethyl]-2-[3,3,3-trifluoropropylthio]-5'-adenylic acid, monoanhydride with dichloromethylenebiphosphonic acid), a selective P2T platelet receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was assessed in a canine model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Placebo or AR-C69931MX (4.0 microg/kg/min for 6 h) pretreatment was administered as an intravenous infusion beginning 15 min before inducing vessel wall injury </plain></SENT>
<SENT sid="3" pm="."><plain>A 300-microA anodal current was applied to the intima of the carotid artery for 180 min or discontinued 30 min after cessation of blood flow due to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="4" pm="."><plain>Each of five control animals developed occlusive <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> within 3 h after induction of vessel wall injury </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, carotid artery blood flow in five of six AR-C69931MX-treated animals was maintained for the duration of the protocol </plain></SENT>
<SENT sid="6" pm="."><plain>Ex vivo platelet aggregation in response to <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> was inhibited at the first measurement time point of 75 min after the start of drug infusion and remained inhibited during drug administration </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time values were increased in the drug-treated group </plain></SENT>
<SENT sid="8" pm="."><plain>Values for both the ex vivo platelet aggregation and the <z:mp ids='MP_0001914'>bleeding</z:mp> times returned to control values shortly after discontinuation of AR-C69931MX </plain></SENT>
<SENT sid="9" pm="."><plain>The results indicate that AR-C69931MX antagonizes the ex vivo and in vivo aggregatory actions of <z:chebi fb="13" ids="16761">ADP</z:chebi>, and displays a rapid <z:hpo ids='HP_0003674'>onset</z:hpo> and offset of action with the ability to prevent occlusive arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="10" pm="."><plain>AR-C69931MX may be suitable for the management of patients who require short-term modulation of platelet function </plain></SENT>
</text></document>